Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

1233 - Management of Brain Metastases in Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Chien Hung Chen

Citation

Annals of Oncology (2018) 29 (suppl_9): ix150-ix169. 10.1093/annonc/mdy425

Authors

C.H. Chen1, M. Huang2, I. Chong3

Author affiliations

  • 1 Graduate Institute Of Medicine, College Of Medicine, Kaohsiung Medical University, 80708 - Kaohsiung City/TW
  • 2 Radiation Oncology, Kaoshiung Medical University Hospital, 807 - Kaohsiung City/TW
  • 3 Faculty Of Medicine, College Of Medicine, Graduate Institute of Medicine, Kaohsiung Medical University, 80708 - Kaohsiung City/TW
More

Resources

Abstract 1233

Background

Brain metastases (BM) are the major cause of death in patients with non-small-cell lung cancer (NSCLC). The use of upfront epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) and the withholding of whole-brain radiation therapy (WBRT) is controversial. We aimed at the impact of WBRT on overall survival (OS).

Methods

A total of 141 EGFR-mutated NSCLC patients with BM were included. All patients received EGFR-TKIs with or without WBRT between 2011 and 2015 at three cancer centers. Patient follow-up was conducted by clinic visits or telephone calls until June 2018. OS was measured from the date of brain metastases. The survival data were collected and analyzed by Kaplan-Meier analysis and the Cox regression method.

Results

All patients had TKIs. The median duration of TKIs use was 12.5 months (95% confidence interval (CI), 10.5-14.4). Ninety-four patients (66.7%) had been treated with WBRT (TKI + WBRT group) with mean radiation dose of 3781±749cGy to brain metastases. With a median follow-up of 20.3 months (95% CI, 16.9-23.7), the median survival after BM was 14.3 months (95% CI, 9.5-18.3) for patients who underwent WBRT (TKI + WBRT group) and 2.3 months (95% CI, 2-2.6) for patients who did not accept WBRT (TKI alone group). The mean survival after BM were 18± 15.2 months and 7.1± 10.8 months in TKI+WBRT group and TKI alone group, respectively (P < 0.001). On multivariate analysis, WBRT, female gender and lung surgery were associated with improved OS (P < 0.001). The 1-year survival rate were 81.9% versus 59.6% in TKI+WBRT group and TKI alone group, respectively (P = 0.002).

Conclusions

EGFR-mutant NSCLC patients with BM benefited from the combination of EGFR-TKIs and WBRT. Further prospective study is warranted.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Inn-Wen Chong.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.